At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 320 enrolled
Drug / intervention
Amphetamine Sulfate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD)
In Brief
A Phase 3 clinical trial evaluating Amphetamine Sulfate and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 320 participants across 31 sites.
Detailed Summary
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartSep 2018
Primary CompletionApr 2019
TodayJul 2026
First PostedSep 6, 2018
Enrollment StartSep 18, 2018
Primary CompletionApr 12, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.8 years ago
Interventions
Amphetamine Sulfatedrug
active experimental AR19
Placebodrug
Matching placebo